How Andrew Hamilton’s VETR and Toltrazuril Solution Advance Pet Care

VETR is set to launch a platform to support pet owners and their furry friends. Recognizing the challenges that pet owners face in finding care for their animals, Andrew Hamilton founded VETR.com, which is a dedicated platform that helps connect pet owners with veterinary professionals. Slated to launch later this year, the platform’s mission is to deliver high-quality, cost-effective care for pets nationwide while also focusing on generic medications and virtual care, changing how modern pet owners manage their animals’ health.

Andrew Hamilton’s Inspiration

The idea for VETR.com stems from the intersection of two different parts of Hamilton’s life: his professional background in biotech and his personal experience as a pet owner. The founder stated, “I’ve worked in drug manufacturing for years—we’re a licensed pharmaceutical compounder, so I’ve seen firsthand how much medications cost versus what people pay… that disconnect made me think: why can’t we do this differently?”

While Hamilton set out to launch VETR.com to address this disconnect, his vision went beyond just building a convenient online pharmacy for pet owners. For him, his passion for improving access to veterinary care was personal. Understanding the real struggles of navigating the complexities of pet health, the platform’s founder aimed to create a solution.

From Challenge to Solution

One of the most persistent yet unfortunately overlooked challenges in animal health is coccidiosis. This parasitic disease is caused by microscopic parasites called Eimeria and is a common intestinal issue that impacts pets, livestock, and companion animals. Coccidiosis is widespread in Australia, with kangaroos, common wombats, and platypuses among the animals that contract it.

Managing outbreaks of coccidiosis can be both costly and time-consuming (not to mention stressful for all parties involved). To address this challenge and the need for a more practical and widely applicable treatment option, the VETR team arrived at the first solution: ToltraMax. This treatment is a high-concentration (10%) oral solution of toltrazuril, designed for companion animal use, including dogs, cats, horses, and other non-food-chain animals.

“Our focus is on supporting pet owners and veterinarians with better tools,” Hamilton says. “ToltraMax reflects that philosophy—it’s practical, effective, and designed with real-world challenges in mind.”

Recognizing the Need for VETR

Earlier this year, Pale Horse Capital invested $21 million in funding to support the further development and expansion of VETR.  As pet ownership rises, access to traditional veterinarian care becomes more challenging. The firm’s investment reflects its recognition of the need for accessible, cost-effective veterinary solutions. Further highlights of the expansion of VETR.com include Pale Horse Capital’s acquisition of HorsePrerace.com, one of the internet’s biggest online retailers of equine health products. VETR.com is currently seeking out online retailers in Australia.

It is important to note that VETR.com won’t replace vet visits; it wasn’t intended to. Rather, the platform was developed to work closely with licensed veterinarians and provide a trusted source for pet owners to access products like ToltraMax while encouraging responsible use through professional guidance.

Currently, ToltraMax is available through Amazon.com, eBay.com, HorsePreRace.com, VETR.com, and toltrazuril.com.

About VETR

VETR is a source where pet owners and breeders can access quick, reliable care when they need it most. Founded by Andrew Hamilton, the platform offers instant access to experienced veterinarians in their area who are trusted for their exceptional care and expertise. Whether you need a routine check-up or urgent care, these highly trained veterinarians can address health concerns promptly while ensuring your animals receive the attention they deserve.

VETR.com is actively working on making ToltraMax more accessible. Additionally, the company has other generic drug applications currently pending in preparation to expand its offerings in animal healthcare.